SCHEMBL6837372

SCHEMBL6837372

COc1ccc(C2=NN(Cc3ccc(NC(=O)CCN4CCCCC4)cc3)C(=O)SC2)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 4/20 0.52
PDE4B Q07343 4/20 0.52
PDE4A P27815 2/20 0.52
PDE4C Q08493 2/20 0.52
PDE3B Q13370 2/20 0.52
PDE3A Q14432 2/20 0.52
MET P08581 1/20 0.52
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
ALOX15 P16050 1/20 0.49
GLA P06280 1/20 0.46
ATM Q13315 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LMNA P02545 2/20 0.45
GAA P10253 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP2D6 P10635 1/20 0.44
TERT O14746 1/20 0.44
TSHR P16473 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6660167 0.99 PDE4B (0.53) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6656893 0.95 PDE4D (0.48) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6659639 0.95 PDE4D (0.49) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6656542 0.94 PDE4D (0.48) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6655608 0.94 PDE4D (0.50) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6662196 0.93 MET (0.50) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6841946 0.93 PDE4B (0.52) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6654582 0.93 PDE4A (0.46) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6659043 0.92 MET (0.51) PDE4DPDE4BPDE4APDE4CPDE3B
SCHEMBL6660949 0.92 PDE4D (0.56) PDE4DPDE4BPDE4APDE4CPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B PDE4D 12/4885PDE4B 4/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.